Sorrento Therapeutics, Inc. announced the addition of Jeffrey Su, Ph.D., as Executive Vice President and Chief Operating Officer. Dr. Su will be responsible for all manufacturing operations at Sorrento, including the analytical and process development laboratories, the newly constructed cGMP manufacturing facility, and all required quality systems. Prior to joining Sorrento, Dr. Su was Chief Scientific and Development Officer at Cytovance Biologics Inc.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0113 USD | -22.07% | +7.62% | -90.85% |
10/04 | Sorrento Therapeutics, Inc. Emerged from Bankruptcy | CI |
15/03 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
1st Jan change | Capi. | |
---|---|---|
-90.85% | 6.14M | |
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |
- Stock Market
- Equities
- SRNE Stock
- News Sorrento Therapeutics, Inc.
- Sorrento Therapeutics, Inc. Appoints Jeffrey Su as Executive Vice President and Chief Operating Officer